Case: We present three cases in which patients that had suffered polytrauma developed heparin-induced thrombocytopenia after the start of heparin treatment for thrombosis. All three patients had high injury severity scores and required major surgery. They all started receiving unfractionated heparin for deep venous thrombosis with or without an asymptomatic pulmonary embolism. The patients were clinically diagnosed with heparin-induced thrombocytopenia after their platelet counts fell or exhibited a delayed recovery. Outcome: Heparin-induced thrombocytopenia and the associated thromboses were successfully treated by discontinuing all forms of heparin treatment and administering argatroban followed by warfarin. Conclusion: Early recognition and clinical diagnosis of heparin-induced thrombocytopenia is necessary for clinicians in cases in which severely injured trauma patients show reductions or delayed recovery in their platelet counts in combination with thrombosis after starting heparin treatment.
Case: We present three cases in which patients that had suffered polytrauma developed heparin-induced thrombocytopenia after the start of heparin treatment for thrombosis. All three patients had high injury severity scores and required major surgery. They all started receiving unfractionated heparin for deep venous thrombosis with or without an asymptomatic pulmonary embolism. The patients were clinically diagnosed with heparin-induced thrombocytopenia after their platelet counts fell or exhibited a delayed recovery. Outcome: Heparin-induced thrombocytopenia and the associated thromboses were successfully treated by discontinuing all forms of heparin treatment and administering argatroban followed by warfarin. Conclusion: Early recognition and clinical diagnosis of heparin-induced thrombocytopenia is necessary for clinicians in cases in which severely injured traumapatients show reductions or delayed recovery in their platelet counts in combination with thrombosis after starting heparin treatment.
Entities:
Keywords:
Argatroban; deep venous thrombosis; heparin‐induced thrombocytopenia; polytrauma; warfarin
Authors: Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Mark Andrew Crowther; Deborah J Cook; Martin Albert; David Williamson; Maureen Meade; John Granton; Yoanna Skrobik; Stephan Langevin; Sangeeta Mehta; Paul Hebert; Gordon H Guyatt; William Geerts; Christian Rabbat; James Douketis; Nicole Zytaruk; Joanne Sheppard; Andreas Greinacher; Theodore E Warkentin Journal: J Crit Care Date: 2010-02-10 Impact factor: 3.425
Authors: Norbert Lubenow; Peter Hinz; Simone Thomaschewski; Theresia Lietz; Michael Vogler; Andrea Ladwig; Michael Jünger; Matthias Nauck; Sebastian Schellong; Kathrin Wander; Georg Engel; Axel Ekkernkamp; Andreas Greinacher Journal: Blood Date: 2009-11-20 Impact factor: 22.113
Authors: Theodore E Warkentin; Jo-Ann I Sheppard; Diane Heels-Ansdell; John C Marshall; Lauralyn McIntyre; Marcelo G Rocha; Sangeeta Mehta; Andrew R Davies; Andrew D Bersten; Tim M Crozier; David Ernest; Nicholas E Vlahakis; Richard I Hall; Gordon G Wood; Germain Poirier; Mark A Crowther; Deborah J Cook Journal: Chest Date: 2013-09 Impact factor: 9.410